Novo Nordisk’s Concizumab Could Be First In New Class For Hemophilia
TFPI Inhibitors Have 20 Years Of Bad History
Executive Summary
Phase III data for the drug showed strong efficacy among hemophilia A and B patients with inhibitors. The drug’s approval would help drive continued segmentation of the hemophilia market.
You may also be interested in...
Pfizer’s Marstacimab Wins In Phase III, But Caution On Market Position, Clotting Remain
The drug showed efficacy in hemophilia A and B with no sign of clots, an issue that historically has dogged anticoagulation agents, but it remains unclear whether that advantage will hold.
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
EU Fast Track Sought For Alzheimer’s, Hemophilia & Multiple Myeloma Drugs
Lecanemab, which could be approved in the US this week for Alzheimer’s disease, is among the latest investigational products that the European Medicine Agency has considered for review under its accelerated assessment pathway.